Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain
Alexander G. Thompson, Elizabeth Gray, Nick Verber, et al.
Brain Communications (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Jonathan Mill, Merit Cudkowicz, Angela Genge, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 12, pp. 1099-1110
Open Access | Times Cited: 522
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Richard J. Mead, Ning Shan, H. Joseph Reiser, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 185-212
Open Access | Times Cited: 261
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Michael Khalil, Charlotte E. Teunissen, Sylvain Lehmann, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 5, pp. 269-287
Closed Access | Times Cited: 111
A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD
Katherine E. Irwin, Pei Jasin, Kerstin E. Braunstein, et al.
Nature Medicine (2024) Vol. 30, Iss. 2, pp. 382-393
Open Access | Times Cited: 62
Current State and Future Directions in the Therapy of ALS
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt, et al.
Cells (2023) Vol. 12, Iss. 11, pp. 1523-1523
Open Access | Times Cited: 56
Fluid biomarkers for amyotrophic lateral sclerosis: a review
Katherine E. Irwin, Udit Sheth, Philip C. Wong, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 28
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
Leonard H. van den Berg, Jeffrey D. Rothstein, Pamela J. Shaw, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 9, pp. 901-912
Closed Access | Times Cited: 24
Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal
Michael Benatar, Joanne Wuu, Martin R. Turner
Brain (2022) Vol. 146, Iss. 7, pp. 2711-2716
Open Access | Times Cited: 51
Blood biomarkers in ALS : challenges, applications and novel frontiers
Ellie Sturmey, Andrea Malaspina
Acta Neurologica Scandinavica (2022) Vol. 146, Iss. 4, pp. 375-388
Open Access | Times Cited: 42
Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross‐sectional multicenter study
Thomas Meyer, Erma Salkic, Torsten Grehl, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1600-1610
Open Access | Times Cited: 29
Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration
Gerry Shaw, Irina Madorsky, Ying Li, et al.
Brain Communications (2023) Vol. 5, Iss. 2
Open Access | Times Cited: 25
Opinion: more mouse models and more translation needed for ALS
Elizabeth Fisher, Linda Greensmith, Andrea Malaspina, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 24
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology
Michael Benatar, Joanne Wuu, Edward D. Huey, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 6, pp. 364-376
Open Access | Times Cited: 12
Advances in the early diagnosis of amyotrophic lateral sclerosis
Pilar H. García‐Casanova, Juan F. Vázquez‐Costa
Expert Review of Neurotherapeutics (2025)
Closed Access | Times Cited: 1
Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis
Michael Benatar, Eric A. Macklin, Andrea Malaspina, et al.
EBioMedicine (2024) Vol. 108, pp. 105323-105323
Open Access | Times Cited: 8
Emerging perspectives of synaptic biomarkers in ALS and FTD
Karrthik Krishnamurthy, Raj Kumar Pradhan
Frontiers in Molecular Neuroscience (2024) Vol. 16
Open Access | Times Cited: 7
Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial
Suma Babu, Katharine Nicholson, Jeffrey D. Rothstein, et al.
Brain (2024) Vol. 147, Iss. 9, pp. 2998-3008
Closed Access | Times Cited: 6
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice
Michael Benatar, Lyle W. Ostrow, Joseph W. Lewcock, et al.
Annals of Neurology (2023) Vol. 95, Iss. 2, pp. 211-216
Open Access | Times Cited: 14
Unsupervised machine learning identifies distinct ALS molecular subtypes in post-mortem motor cortex and blood expression data
Heather Marriott, Renata Kabiljo, Guy P Hunt, et al.
Acta Neuropathologica Communications (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 14
Brain–body mechanisms contribute to sexual dimorphism in amyotrophic lateral sclerosis
Sarah Jacob, Suk‐young Lee, Seung Hyun Kim, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 8, pp. 475-494
Closed Access | Times Cited: 5
A microRNA diagnostic biomarker for amyotrophic lateral sclerosis
Sandra Anne Banack, Rachael A. Dunlop, Paul Mehta, et al.
Brain Communications (2024) Vol. 6, Iss. 5
Open Access | Times Cited: 5
CSF and blood levels of Neurofilaments, T-Tau, P-Tau, and Abeta-42 in amyotrophic lateral sclerosis: a systematic review and meta-analysis
Elmira Agah, Helia Mojtabavi, Atefeh Behkar, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
Keiko Imamura, Yuishin Izumi, Makiko Nagai, et al.
EClinicalMedicine (2022) Vol. 53, pp. 101707-101707
Open Access | Times Cited: 21
Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.
Mehdi Brousse, Constance Delaby, Elisa De La Cruz, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 7, pp. 1919-1927
Open Access | Times Cited: 11
Blood level of neurofilament light chain as a biomarker for neurological disorders
Martin R. Turner, Alexander G. Thompson, Charlotte E. Teunissen
BMJ Medicine (2025) Vol. 4, Iss. 1, pp. e000958-e000958
Open Access
Page 1 - Next Page

Scroll to top